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Abstract
Peritoneal carcinomatosis (PC) is one manifestation of 
metastatic colorectal cancer (CRC). Tumor growth on 
intestinal surfaces and associated fluid accumulation 
eventually result in bowel obstruction and incapacitat-
ing levels of ascites, which profoundly affect the qual-
ity of life for affected patients. PC appears resistant 
to traditional 5-fluorouracil-based chemotherapy, and 
surgery was formerly reserved for palliative purposes 
only. In the absence of effective treatment, the histori-
cal prognosis for these patients was extremely poor, 
with an invariably fatal outcome. These poor outcomes 
likely explain why PC secondary to CRC has received 
little attention from oncologic researchers. Thus, data 
are lacking regarding incidence, clinical disease course, 
and accurate treatment evaluation for patients with PC. 
Recently, population-based studies have revealed that 
PC occurs relatively frequently among patients with 
CRC. Risk factors for developing PC have been identi-
fied: right-sided tumor, advanced T-stage, advanced 
N-stage, poor differentiation grade, and younger age 
at diagnosis. During the past decade, both chemother-
apeutical and surgical treatments have achieved prom-
ising results in these patients. A chance for long-term 
survival or even cure may now be offered to selected 
patients by combining radical surgical resection with 
intraperitoneal instillation of heated chemotherapy. 
This combined procedure has become known as hy-
perthermic intraperitoneal chemotherapy. This edito-
rial outlines recent advancements in the medical and 
surgical treatment of PC and reviews the most recent 
information on incidence and prognosis of this disease. 
Given recent progress, treatment should now be con-
sidered in every patient presenting with PC.  
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cancer (CRC) is characterized by the development of  
solid tumor deposits on the peritoneal surface[1]. Cell 
shedding from the primary tumor is thought to be re-
sponsible for these peritoneal deposits, which may occur 
spontaneously or as a result of  spillage during surgical 
procedures. Attachment of  tumor cells to peritoneal me-
sothelial cells involves neoangiogenesis and is mediated 
by several growth factors[2]. Tumor implantation and 
growth may lead to invasion of  any organ or structure 
that is covered by peritoneum. 
Common sites for peritoneal implants are the omen-
tum, mesentery, bowel surface, pouch of  Douglas, right 
paracolic gutter, and diaphragm[3,4]. Patients initially 
present with nonspecific symptoms such as abdominal 
discomfort, nausea, weight loss, cachexia, and fatigue; 
however, these symptoms are often indistinguishable 
from more general features of  malignant disease. The 
tumor growth on intestinal surfaces and associated fluid 
accumulation eventually result in signs of  bowel ob-
struction[5] and incapacitating volumes of  ascites[6,7]. Pre-
viously, providers were reluctant to treat these patients 
because of  their extremely poor prognosis and invariably 
fatal outcomes[8-10]. Therefore, PC resulting from CRC 
had received little attention from oncologic research-
ers. Hence, data was lacking regarding incidence, clinical 
disease course, and accurate treatment evaluation for 
patients with PC. 
Since the 1980s, PC research has attracted renewed 
interest because of  the observation that a subgroup of  
patients presents solely with peritoneal tumor implants 
without systemic metastases[11,12]. This finding spurred 
the development of  aggressive surgical treatment mo-
dalities which combined radical cytoreductive surgery 
with intraperitoneal chemotherapy[13-17]. With this ap-
proach, prolonged overall survival and even disease cure 
have been reported[8,18-26]. Here, we will discuss the recent 
advances in the characterization and treatment of  these 
patients. 
INCIDENCE OF PC
The extent of  peritoneal disease is frequently underes-
timated by imaging modalities[27], and the presence of  
peritoneal involvement often remains unknown until a 
laparotomy is performed. This uncertainty in preopera-
tive diagnosis results from the low sensitivity and speci-
ficity of  imaging techniques such as abdominopelvic 
ultrasound and computed tomography. The small size 
of  tumor deposits (typically less than 1 cm) negatively 
affects sensitivity[27-30]. Furthermore, peritoneal spread of  
tumor cells characteristically follows the anatomic out-
line of  normal abdominal structures, making radiologic 
detection more challenging.
Underestimation of  PC due to poor preoperative 
imaging diagnostics, combined with the aforementioned 
lack of  interest, likely explains the virtual absence of  
data on PC incidence. Most available data were retrieved 
from single hospital-based studies that reported inci-
dence of  PC encountered during laparotomy. In the larg-
est study, which included 2756 patients with CRC, 214 
(8%) patients were diagnosed with synchronous PC and 
135 (5%) with metachronous disease[10]. Two older stud-
ies, also single hospital-based, reported that 10% to 15% 
of  patients with colon cancer presented with PC[9,31]. 
Recently, two population-based studies reported the in-
cidence of  synchronous PC in The Netherlands (4.8%) 
and in Sweden (4.3%)[32,33]. Risk factors for developing 
PC include right-sided tumor, advanced T-stage, ad-
vanced N-stage, poor differentiation grade, and younger 
age at diagnosis. 
In clinical studies, metachronous PC is reported in 
4% to 12% of  patients following curative resection for 
colon cancer and in 2% to 19% of  patients following 
curative resection for rectal cancer[34]. In patients under-
going repeat procedures for CRC following primary cu-
rative resection, 21% to 44% of  patients are diagnosed 
with peritoneal tumor deposits[35,36]. In autopsy studies, 
PC is found in up to 40% of  patients who die from 
colorectal carcinoma[37,38]. On a population level, 4.2% of  
Swedish patients with CRC developed metachronous PC 
following initial treatment[33]. Risk factors for developing 
metachronous PC are similar to those for synchronous 
PC, but also include initial emergency procedures and 
non-radical initial tumor resection[33]. 
TREATMENT
Systemic treatment
Few studies have been published describing the effec-
tiveness of  systemic chemotherapy in patients with PC. 
Due to an inability to accurately measure tumor load 
and treatment response, patients with peritoneal tumors 
usually do not meet the inclusion criteria for randomized 
trials[39]. The few studies describing chemotherapeutic 
treatment response focus on systemic 5-fluorouracil 
(5-FU) and leucovorin using retrospective analysis. The 
results invariably show a disappointing response to sys-
temic treatment and a poor prognosis compared to other 
metastatic sites. A French prospective multicenter study 
of  118 patients with PC of  colorectal origin showed a 
median survival of  only 5.2 mo[40]. In a large series of  
CRC patients, which included 392 patients with perito-
neal involvement, Jayne et al[10] showed a median survival 
of  7 mo. Chu et al [9] reported a median survival of  6 mo 
in a series of  45 patients who were treated primarily with 
5-FU and leucovorin. A sub-analysis by Köhne et al[41] 
of  patients with PC treated with 5-FU-based therapy 
showed a median survival of  7.7 mo. Slightly better 
results were reported by Bloemendaal et al[8], who de-
scribed 50 patients with PC but without hematogenous 
metastases who were treated with systemic chemother-
apy and palliative surgery. Their overall median survival 
was 12.6 mo, with a 2-year survival rate of  approximately 
18%[8,24]. However, selection bias probably explains these 
findings, because these patients were initially referred for 
hyperthermic intraperitoneal chemoperfusion (HIPEC)-
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treatment but eventually randomized to the study control 
group. It is conceivable that these patients were healthier 
and their PC disease was more limited compared to the 
average PC patient. 
A few studies have aimed to describe the effect of  
newer chemotherapeutic combinations, such as oxalipla-
tin plus irinotecan[8,42,43]. Results are conflicting and re-
quire careful interpretation. Many of  these studies were 
performed to compare systemic treatment with surgical 
treatment. Selection bias may play a role in these stud-
ies because only patients in good condition with limited 
disease and without systemic metastases were eligible. 
Nevertheless, the median survival of  23 mo, as described 
by Elias et al[18] and obtained with modern systemic che-
motherapy, is remarkable and dispels the notion that PC 
is chemotherapy-resistant. A similar conclusion may be 
drawn from the only population-based study to investi-
gate this topic thus far. From 1995 to 2008, the admin-
istration of  chemotherapy to patients with PC gradually 
increased, from 16% to 46% (P = 0.001), with the treat-
ment rate rising to 64% for younger patients[41]. However, 
a survival benefit was only apparent after 2005 when 
modern chemotherapy schedules were introduced[44]. 
Introduction of  targeted therapies, including mono-
clonal antibodies specifically targeted to epidermal 
growth factor receptor and vascular endothelial growth 
factor, has resulted in a significantly increased survival 
among patients with metastasized CRC[41,45,46]. Although 
these agents are now routinely included in the treatment 
of  patients with stage Ⅳ disease, only one small retro-
spective study has evaluated the effect of  adding targeted 
therapies in patients with PC; a survival of  22.4 mo was 
observed when biologicals were added to first line of  
treatment in this patient group[47].
Cytoreductive surgery and intraperitoneal chemotherapy
The observation that some patients present with PC in 
the absence of  systemic metastases has led to the hy-
pothesis that PC results from locoregional spread rather 
than systemic metastasis. This belief  has encouraged sur-
gical oncologists to examine possibilities for locoregional 
therapies. In the 1980s and 1990s, physicians and re-
searchers developed new treatment strategies consisting 
of  aggressive cytoreductive surgery plus intraperitoneal 
chemotherapy, often combined with hyperthermia.
Surgical procedures invariably start with a careful and 
systematic abdominal exploration and registration of  the 
extent of  peritoneal disease. The abdomen is divided in 
13 regions and for each region, the number and size of  
tumor deposits are assessed and recorded. The sum of  
these scores represents the peritoneal cancer index (PCI), 
which ranges from 0 to 39. For PC resulting from CRC, 
a PCI score of  15 or more is generally accepted as exclu-
sion criterion for HIPEC. In The Netherlands, the sim-
plified PCI (sPCI) is commonly used to describe the PC 
involvement of  9 regions of  the abdomen[24]. The PCI 
and sPCI are well-known predictive outcome indices for 
patients undergoing cytoreductive surgery and periop-
erative chemotherapy[48,49].
During cytoreductive surgery, surgeons attempt to 
remove all visible tumor deposits from the peritoneal 
surface. To achieve a radical resection, resection of  
grossly involved organs may be required. Additionally, 
peritonectomy may be performed[15]. Resection com-
pleteness is recorded using the completeness of  cytore-
duction score (CCR). A CCR-0 score indicates that no 
macroscopic peritoneal tumor remains following cytore-
duction. A CCR-1 score occurs when tumor nodules less 
than 2.5 mm persist following cytoreduction. Residual 
disease measuring 2.5 mm to 2.5 cm is scored as CCR-2. 
A CCR-3 score indicates the presence of  tumor nod-
ules greater than 2.5 cm, or a confluence of  unresect-
able tumor nodules at any site within the abdomen or 
pelvis[50]. Alternatively, the R1-R2a-R2b scoring system 
classifies R1 as no macroscopic residual tumor, R2a as 
macroscopic residual disease less than 2.5 mm, and R2b 
as tumor deposits greater than 2.5 mm[24]. Treatment 
outcomes are poorer in the presence of  residual tumor 
following optimal cytoreduction, particularly for residual 
tumor diameters exceeding 2.5 mm. It is hypothesized 
that 2.5 mm is the maximum penetration depth of  che-
motherapeutic agents[48]. 
After macroscopically complete cytoreduction, in-
traperitoneal chemotherapy is administered to eradicate 
microscopic disease. This chemotherapy can be admin-
istrated immediately following surgery in the operating 
room, usually in combination with HIPEC or on post-
operative days 1 to 5 (early postoperative intraperitoneal 
chemotherapy). HIPEC perfusion may be performed 
with a closed abdomen, or with an open “coliseum tech-
nique”. Chemotherapeutic agents and doses vary widely 
between centers worldwide, with mitomycin C and oxali-
platin being the most frequently used agents. 
Only one completed phase Ⅲ randomized trial 
investigating the outcome of  surgical intraperitoneal 
treatment has been published to date. Verwaal et al[24,25,51] 
reported a significant increase in median overall survival 
among patients treated with cytoreductive surgery and 
HIPEC, as compared to patients receiving standard pal-
liative care using systemic 5-FU and leucovorin. The 
promising outcomes observed in this study have con-
vinced many surgeons to accept this technique as stan-
dard of  care for selected patients with PC, and HIPEC 
treatment is now offered in specialized centers all over 
the world. However, this study was heavily criticized 
for not including a control group of  patients receiving 
cytoreductive surgery only. Therefore, it remains unclear 
whether cytoreductive surgery and HIPEC are both 
required to improve survival, or if  the observed benefit 
was due to a single component[52]. Ideally, these ques-
tions should be addressed in randomized trials. However, 
this type of  study has proven difficult to implement, as 
demonstrated by a phase Ⅲ trial in France that failed 
to enroll enough patients due to patient dissatisfaction 
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with randomization[53]. Recently, investigations of  cyto-
reductive surgery and HIPEC in PC animal models have 
provided a sound scientific rationale for the application 
of  intraperitoneal chemotherapy in conjunction with cy-
toreductive surgery[54-56], although the additional value of  
hyperthermia is questionable[54]. 
The best available clinical evidence now comes from 
multi-institutional registries[18-23]. These data require care-
ful interpretation, as surgeon experience, technique and 
perioperative care differs widely between institutions[57]. 
However, reported median survival rates of  up to 63 mo 
following cytoreductive surgery and HIPEC with limited 
postoperative morbidity and mortality[58,59] suggest that 
treatment should be considered in all patients with PC 
secondary to CRC. 
In conclusion, PC of  colorectal origin was formerly 
considered untreatable, with an extremely poor progno-
sis. Recent treatment advances using modern systemic 
chemotherapy or cytoreductive surgery combined with 
HIPEC have improved patient outcomes. In our opinion, 
treatment should be considered for every patient present-
ing with PC due to CRC. However, further understanding 
of  PC pathogenesis, optimal diagnostics and treatment 
requires ongoing experimental and clinical research. 
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